Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies

We have developed a novel real‐time quaking‐induced conversion RT‐QuIC‐based assay to detect alpha‐synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients. This assay can detect alpha‐synuclein aggregation in Dementia with Lewy bodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fairfoul, Graham, McGuire, Lynne I., Pal, Suvankar, Ironside, James W., Neumann, Juliane, Christie, Sharon, Joachim, Catherine, Esiri, Margaret, Evetts, Samuel G., Rolinski, Michal, Baig, Fahd, Ruffmann, Claudio, Wade‐Martins, Richard, Hu, Michele T. M., Parkkinen, Laura, Green, Alison J. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048391/
https://www.ncbi.nlm.nih.gov/pubmed/27752516
http://dx.doi.org/10.1002/acn3.338
Descripción
Sumario:We have developed a novel real‐time quaking‐induced conversion RT‐QuIC‐based assay to detect alpha‐synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients. This assay can detect alpha‐synuclein aggregation in Dementia with Lewy bodies and Parkinson's disease cerebrospinal fluid with sensitivities of 92% and 95%, respectively, and with an overall specificity of 100% when compared to Alzheimer and control cerebrospinal fluid. Patients with neuropathologically confirmed tauopathies (progressive supranuclear palsy; corticobasal degeneration) gave negative results. These results suggest that RT‐QuiC analysis of cerebrospinal fluid is potentially useful for the early clinical assessment of patients with alpha‐synucleinopathies.

Ejemplares similares